Article
γT -S195A thrombin reduces the anticoagulant effects of dabigatran in vitro and in vivo.
Journal of thrombosis and haemostasis : JTH - 1 Jul 2014
Sheffield W P, Lambourne M D, Eltringham-Smith L J, Bhakta V, Arnold D M, Crowther M A
Abstract excerpt
BACKGROUND: Dabigatran etexilate (DE) is an oral direct thrombin inhibitor used to prevent strokes in patients with atrial fibrillation. No licensed DE antidote is currently available. We hypothesized that active site-mutated S195A thrombin (S195A-IIa) and/or its trypsinized derivative (γT -S195A-IIa) would sequester dabigatran, the active form of DE, and reduce its anticoagulant effects. OBJECTIVE: To assess...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
